



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Date: 14th February, 2026

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.

Sub: Submission of Unaudited Financial Results for the quarter ended 31st December, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code: 536565

Scrip Id: NOVELIX

Respected Sir/Madam,

Pursuant to our earlier submission dated 12th February, 2026 vide acknowledgement number 12143717 and the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), we hereby submit revised Unaudited Financial Results of the company for the quarter ended 31st December, 2025 along with the limited review report of the auditors thereon (**due to typographical error in the limited review report**) which were approved by the Board of Directors at their meeting held on 12th February, 2026.

A copy of the results along with the limited review report of auditors is enclosed herewith.

The said meeting commenced at 05:00 P.M. and concluded at 05:30 P.M.

Kindly acknowledge the receipt.

Thanking You,
Yours sincerely,

For Novelix Pharmaceuticals Limited

Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



CVS Balachandra Rao & Co.,
Chartered Accountants

Limited Review Report on Standalone Unaudited Quarterly Financial Results of Novelix Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of Directors
Novelix Pharmaceuticals Limited

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Novelix Pharmaceuticals Limited** for the quarter ended on 31st December, 2025, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CVS Balachandra Rao & Co
Chartered Accountants
ICAI Firm Registration Number: 0075875


CVS Balachandra Rao
Partner



Membership Number: 204580
UDIN: 26204580BIBNZB8438
Place: Hyderabad
Date: 12-02-2026

D.No:3-6-108/1, Flat No:203, Sanatana Etemal, Street No:19, Himayat Nagar, Hyderabad - 500 029. Telangana.

Mobile : 9849035315, 9010624455

Email : cacvsbala@gmail.com, cvsbala67@gmail.com, Website : www.cabrc.in

Branch Office : D No. 11-33-7B, 2nd Floor, Tatakulavari Street. Samarang Chowk. Vijayawada - 520 001. A.P.




**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE
QUARTER ENDED 31st DECEMBER 2025**

PARTICULARS	Quarter Ended	Preceding Quarter Ended	Correspondin g Quarter Ended in Previous Year	9 Months Ended	Correspondin g 9 Months Ended in Previous Year	YEAR ENDED
	31.12.2025 (UNAUDITED)	30.09.2025 (UNAUDITED)	31.12.2024 (UNAUDITED)	31.12.2025 (UNAUDITED)	31.12.2024 (UNAUDITED)	31.03.2025 (AUDITED)
1. INCOME						
INCOME FROM OPERATIONS	4,840.25	3,635.89	529.98	10,711.26	985.75	3,071.85
OTHER INCOME	0.02	3.25	0.11	3.26	1.60	1.60
TOTAL INCOME	4,840.27	3,639.14	530.09	10,714.52	987.35	3,073.44
2. EXPENSES						
PURCHASES	4,828.08	3,668.48	561.14	10,746.06	900.64	2,922.25
COST OF MATERIALS CONSUMED	-	-	-	-	-	-
MANUFACTURING EXPENSES	-	-	-	-	-	-
INCREASE/(DECREASE) IN STOCK IN TRADE	(143.18)	(149.67)	(58.95)	(364.49)	28.35	35.12
RENT	-	-	-	-	-	-
EMPLOYEE BENEFITS EXPENSE	17.30	14.18	0.78	47.93	6.13	6.86
FINANCE COSTS	-	-	-	-	-	-
DEPRECIATION AND AMORTISATION EXPENSES	3.03	1.38	0.49	5.50	1.46	3.80
OTHER EXPENSES	6.73	32.89	13.84	62.38	59.49	93.08
TOTAL EXPENSES	4,711.96	3,567.25	517.29	10,497.38	996.07	3,061.11
3. PROFIT/(LOSS) FROM BEFORE EXCEPTIONAL ITEMS AND TAX (1- 2)	128.31	71.89	12.80	217.14	(8.72)	12.33
4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS						
5. PROFIT/(LOSS) FROM CONTINUING OPERATIONS BEFORE TAX (3-4)	128.31	71.89	12.80	217.14	(8.72)	12.33
6. TAX EXPENSES	27.87	18.57	(1.99)	52.67	1.07	3.88
-CURRENT TAX	28.80	18.03	-	50.37	-	2.96
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	-	-	-	-	-	-
-DEFERRED TAX (NET)	(0.93)	0.54	(1.99)	2.31	1.07	0.92
7. NET PROFIT/(LOSS) FROM CONTINUING OPERATIONS AFTER TAX (5-6)	100.44	53.31	14.79	164.46	(7.65)	8.45

Novelx Pharmaceuticals limited
(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat
Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com





Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

8.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS						
9.TAX EXPENSES FOR DISCONTINUED OPERATIONS						
10.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)						
11.PROFIT/(LOSS) FOR THE PERIOD (7+10)	100.44	53.31	14.79	164.46	(7.65)	8.45
12.OTHER COMPREHENSIVE INCOME						
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-	-
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
13.TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)	100.44	52.47	14.79	164.46	(7.65)	8.45
14. PAID UP EQUITY SHARE CAPITAL	1721.50	1448.00	995.00	1721.50	995.00	995.00
15.EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION) :						
(i) BASIC	0.58	0.37	0.15	0.96	(0.08)	0.08
(ii) DILUTED	0.85	0.49	0.16	1.43	(0.08)	0.09
16.EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :						
(i) BASIC						
(ii) DILUTED						
17.EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION):						
(i) BASIC	0.58	0.37	0.15	0.96	(0.08)	0.08
(ii) DILUTED	0.85	0.49	0.16	1.43	(0.08)	0.09

Notes:

1. The above Unaudited Financial Results of the company for the quarter ended December 31, 2025 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on 12th February, 2026.



Novelix Pharmaceuticals limited (Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com
www.novelixpharma.com




Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

2. The Company has only one business segment ' Pharmaceutical Research & Analysis and Manufacturing & Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). The Company is not carrying any activity in the segments Investment in Shares, Trading in shares, Foods and Finance.
3. Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4. These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5. The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity ' Pharmaceutical Research & Analysis and Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6. The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website <https://novelixpharma.com>

By the order of the Board
For Novelix Pharmaceuticals Limited

Venkat



Venkateshwarlu Pulluru
(Whole-time director)

DIN: 02076871

Date: 12/02/2026

Place: Hyderabad

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com